Good point. There is also the article written by Ms. Bonstein around the same time touting how valuable CFOs are to the drug development process and serve as integral strategic advisors in small biotechs. Setting aside the argument that she actually didn't adhere to many of the characteristics she touted (keeping spending low in early years and keeping projects on time without delay), one might read the article and question whether its promotion benefits ADXS at all, or rather, benefits the author who may know she has only a limited amount of additional tenure at her present company and could use the article as part of her next job search effort. Perhaps this is also a piece of the puzzle related to the black out.
News 
Market Data 
Discover 
